# Multiperson Review: HTA Methodology Solution
**Project:** Evidence Integrity Suite (Bias Correction + Information Adequacy)
**Date:** February 14, 2026
**Reviewers:** Internal Expert Panel

---

## 1. Reviewer A: The Senior HTA Methodologist
**Focus:** Statistical Rigor & HTA Theory

### 🟢 Commendations
*   **Conceptual Integration:** The combination of *Publication Bias Correction* (Trim-and-Fill) with *Information Adequacy* (OIS) is theoretically sound. Most HTA bodies treat these as separate checklists; unifying them into a single "Evidence Class" is a strong methodological advance.
*   **Fragility as a Predictor:** Using the *Fragility Index* as a target variable for the predictive model is clever. It moves fragility from a descriptive statistic to a predictive risk factor.

### 🔴 Critical Concerns
*   **The "Trim-and-Fill" Limitation:** While standard, Trim-and-Fill is known to perform poorly in the presence of high heterogeneity ($I^2$). The pipeline applies it universally. A "Production" version should include *Selection Models* (e.g., Copas) as a sensitivity analysis for high-$I^2$ datasets.
*   **OIS Approximation:** In the `unified_hta_validation.R` script, the Optimal Information Size (OIS) uses a simplified generic event rate. For a true "Gold Standard" classification, the OIS must be calculated using the *specific control group event rate* from each meta-analysis.
*   **Bias Detection:** Egger's test has low power when $k < 10$. The dashboard flags bias even for smaller $k$, which might lead to false alarms.

**Verdict:** **Methodologically Promising**, but requires refinement of the OIS calculation before being used for reimbursement decisions.

---

## 2. Reviewer B: The Clinical Guideline Developer
**Focus:** Usability & Decision Making

### 🟢 Commendations
*   **The Dashboard:** The `HTA_Dashboard.html` is exactly what panels need. We don't want to see R code or raw p-values; we want to see "Gold Standard" vs. "High Risk." The traffic light system is intuitive.
*   **"Premature" Classification:** Identifying results that are *statistically significant* but *underpowered* is a game-changer. This prevents the "rush to guidelines" based on flimsy early trials.

### 🔴 Critical Concerns
*   **Actionability:** What do I do with a "Robust (Bias-Corrected)" result? Does that mean I fund the drug but at a lower price? The dashboard needs a "Guideline Recommendation" column (e.g., "Downgrade Certainty" vs. "Reject").
*   **Clinical Context:** The tool treats a Risk Difference (RD) of 0.001 the same as 0.1. A "statistically robust" result might still be clinically meaningless. The tool needs a filter for *Minimal Clinically Important Difference (MCID)*.

**Verdict:** **Highly Usable**. The "Premature" category alone makes this tool valuable for guideline committees.

---

## 3. Reviewer C: The Lead Data Scientist
**Focus:** Code Quality, Reproducibility & ML

### 🟢 Commendations
*   **Pipeline Architecture:** The modular design (`bias_correction` -> `unified_validation` -> `predict_decay`) is clean and maintainable.
*   **Error Handling:** The scripts handle missing data and join errors gracefully (e.g., the fix for `analysis_id` types was correctly implemented).
*   **Model Performance:** An AUC of 0.895 is exceptional for this domain.

### 🔴 Critical Concerns
*   **Data Simulation (Critical):** In `unified_hta_validation.R`, line 48: `bias_results[, total_n := k * 150]`. **This is a hard blocker.** You are simulating total sample size rather than reading it from the RDS files. This invalidates the specific "Gold Standard" labels for the demo data. *Fix:* The script must read the actual $N$ from the source files.
*   **Feature Leakage Risk:** The predictive model uses `I2` and `inf_frac` to predict fragility. Since fragility is often correlated with low $N$ (and thus `inf_frac`), there is a risk of circularity. The high AUC might be overfitting to sample size.

**Verdict:** **Code is Clean, but Data Integrity needs a Patch.** The simulation of $N$ must be replaced with real extraction for the final release.

---

## ⚖️ Consensus Verdict & Next Steps

**Overall Rating:** ⭐⭐⭐⭐ (4/5)

The project successfully identifies the "Biggest Issues" in HTA (Bias & Premature Conclusions) and offers a workable solution. The **Dashboard** is a standout deliverable.

**Immediate "Must-Fix" Items:**
1.  **Replace Mock Data:** Modify `unified_hta_validation.R` to extract the true `Total N` and `Control Rate` from the `.rds` files instead of using placeholders.
2.  **Refine OIS:** Implement exact power calculations based on the extracted event rates.

**Strategic Recommendation:**
Deploy the dashboard as a "Beta" for scoping reviews, but implement the **Data Extraction Patch** before using it for any definitive HTA reports.
